Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF)
(FSE: 31R) (“Revive” or the “Company”), a specialty
cannabis company focused on the research, development and
commercialization of novel cannabinoid-based products, today
announced the introduction of RELICANN™, the Company’s hemp-based
and medical cannabis brand designed for the health and
wellness and medical cannabis consumer. The Company’s first
product under the RELICANN™ brand is RELICANN™ hemp-based
Cannabidiol (“CBD”) gum, which will be available in Canada in the
fourth-quarter of 2018.
“We are excited to introduce the RELICANN™
brand, which focuses on the health and wellness and medical
cannabis market targeting those who seek novel dosage forms of
hemp-based and cannabis solutions over conventional ones,” said
Fabio Chianelli, President of Revive. “RELICANN™ hemp-based
CBD gum will be our first of several unique dosage forms of
hemp-based and cannabis products to be launched in Canada,
including Tetrahydrocannabinol (THC) and combination products of
various ratios of CBD and THC.”
RELICANN™ hemp-based CBD gum is a patented
controlled-release cannabinoid chewing gum containing 50 mg of hemp
oil and 10 mg of CBD. Based on an oral mucosal delivery
system a research study has shown the absorption rate of CBD to be
at least 75% in just 30 minutes of chewing. The RELICANN™
hemp-based CBD gum is a distinct and alternative option from
traditional oral forms of hemp (i.e. capsules and oils) and a
convenient and discreet way to enjoy the health benefits of hemp.
It has been widely established that the potential advantages
of medical chewing gum over conventional dosage forms are faster
onset of action, higher bioavailability (absorption in the oral
mucosa, while bypassing the first-pass hepatic metabolism),
pleasant taste, easy for administration while promoting better
compliance (no need for water), higher acceptance for those who
find swallowing tablets difficult, and fewer side effects.
The RELICANN™ product line up will be a robust
assortment of unique dosage and combination offerings of CBD and
THC, such as, but not limited to, chewing gums, topicals, and
alternate oral forms, putting an emphasis on medical, health and
wellness. A number of RELICANN™ products will be introduced
to the Canadian marketplace as recognized under the proposed
regulations of Cannabis and Health Canada’s Natural Health Products
and Food and Drug regulations, with the objective to sell through
legalized distribution channels, national retailers in the food,
drug, mass market, and specialty and natural retail channels.
About Revive Therapeutics
Ltd.
Revive Therapeutics Ltd. (TSX VENTURE: RVV)
(OTCQB: RVVTF) (FSE: 31R) is a specialty cannabis company focused
on the research, development and commercialization of novel
cannabinoid-based products. Revive is commercializing
patent-protected, best-in-class cannabis-based products with first
mover advantage in the multi-billion cannabis and wellness
market. The Company’s first commercial product is a
proprietary hemp-based cannabidiol (“CBD”) chewing gum, RELICANN™,
for the health and wellness and medical cannabis market offering a
better alternative over conventional products. The Company’s
novel cannabinoid delivery technology is being advanced to fill the
unmet medical needs for diseases and disorders such as pain,
inflammation, and wound care. Revive’s cannabinoid pharmaceutical
portfolio focus’ on rare liver diseases, which the FDA granted to
the Company orphan drug designation for CBD in the treatment of
autoimmune hepatitis.
For more information visit:
www.ReviveThera.com.
Neither the TSX-V nor its Regulation Services
Provider (as that term is defined in the policies of the TSX-V)
accepts responsibility for the adequacy or accuracy of this
release.
Revive Therapeutics Ltd. Cautionary Note
Regarding Forward-Looking Statements
This news release includes certain information
and statements about management's view of future events,
expectations, plans and prospects that constitute “forward-looking
information” that involves known and unknown risks and
uncertainties, which are not comprised of historical facts, and
most of which are beyond the control of Revive. Forward-looking
statements include estimates and statements that describe Revive’s
future plans, objectives or goals, including words to the effect
that Revive or its management expects a stated condition or result
to occur. Forward-looking statements may be identified by such
terms as “believes”, “anticipates”, “intends”, “expects”,
“estimates”, “may”, “could”, “would”, “will”, “potential”, or
“plan”, and similar expressions. Specifically, forward-looking
statements in this news release include, without limitation,
statements regarding: the introduction of RELICANN™, the Company’s
hemp-based wellness and medical cannabis brand designed for the
health and wellness and medical cannabis consumer; RELICANN™, which
will be available in Canada in the fourth-quarter of 2018;
RELICANN™ hemp-based CBD gum will be our first of several
unique dosage forms of hemp-based and cannabis products to be
launched in Canada, including Tetrahydrocannabinol (THC) and
combination products of various ratios of CBD and THC;
RELICANN™ hemp-based CBD gum is a patented controlled-release
cannabinoid chewing gum containing 50 mg of hemp oil and 10 mg of
CBD. Based on an oral mucosal delivery system research study
has shown the absorption rate of CBD is 80% in just 30 minutes of
chewing; RELICANN™ products will be introduced to the Canadian
marketplace as recognized under the proposed regulations of
Cannabis and Health Canada’s Natural Health Products and Food and
Drug regulations, with the objective to sell through legalized
distribution channels, national retailers in the food, drug, mass
market, and specialty and natural retail channels; Revive’s drug
research and development, and commercialization plans; Revive’s
branded cannabis-based products; Revive’s Bucillamine program; the
timing of operations; and estimates of market conditions. These
statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results or events, performance,
or achievements of Revive to differ materially from those
anticipated or implied in such forward-looking statements. Since
forward-looking statements are based on assumptions and address
future events and conditions, by their very nature they involve
inherent risks and uncertainties. Revive believes that the
expectations reflected in these forward-looking statements are
reasonable, but there can be no assurance that actual results will
meet management's expectations. In formulating the forward-looking
statements contained herein, management has assumed: that business
and economic conditions affecting Revive will continue
substantially in the ordinary course and will be favourable to
Revive; that clinical testing results will justify
commercialization of the Revive’s product candidates; that Revive
will be able to obtain all requisite regulatory approvals to
commercialize its product candidates; that such approvals will be
received on a timely basis; and, that Revive will be able to find
suitable partners for development and commercialization of its
product candidates on favourable terms. Although these assumptions
were considered reasonable by management at the time of
preparation, they may prove to be incorrect and no assurance can be
given that such events will occur in the disclosed time frames or
at all.
Factors that may cause actual results to differ
materially from those anticipated by these forward-looking
statements include: uncertainties associated with obtaining
regulatory approval to perform clinical trials and market products;
the need to establish additional corporate collaborations,
distribution or licensing arrangements; Revive’s ability to raise
additional capital if and when necessary; intellectual property
disputes; increased competition from pharmaceutical and
biotechnology companies; changes in equity markets, inflation, and
changes in exchange rates; and other factors as described in detail
in Revive's Management's Discussion & Analysis for the period
ended June 30, 2017 and Revive's other public filings, all of which
may be viewed on SEDAR (www.sedar.com).
Given these risks and uncertainties, readers are cautioned
not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this
cautionary statement. Except as required by law, Revive disclaims
any intention and assumes no obligation to update or revise any
forward-looking statements to reflect actual results, whether as a
result of new information, future events, changes in assumptions,
changes in factors affecting such forward-looking statements or
otherwise.
For more information please contact:
Craig LeonChief Executive OfficerRevive
Therapeutics Ltd.Tel: (416) 272-5525Email:
craig@revivethera.comWebsite:
www.Revivethera.com
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/1a89ed2a-9645-4a4a-b39b-66b077aa3aaa
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Jul 2023 to Jul 2024